Recent insights into the function of autophagy in cancer
- PMID: 27664235
- PMCID: PMC5066235
- DOI: 10.1101/gad.287524.116
Recent insights into the function of autophagy in cancer
Abstract
Macroautophagy (referred to here as autophagy) is induced by starvation to capture and degrade intracellular proteins and organelles in lysosomes, which recycles intracellular components to sustain metabolism and survival. Autophagy also plays a major homeostatic role in controlling protein and organelle quality and quantity. Dysfunctional autophagy contributes to many diseases. In cancer, autophagy can be neutral, tumor-suppressive, or tumor-promoting in different contexts. Large-scale genomic analysis of human cancers indicates that the loss or mutation of core autophagy genes is uncommon, whereas oncogenic events that activate autophagy and lysosomal biogenesis have been identified. Autophagic flux, however, is difficult to measure in human tumor samples, making functional assessment of autophagy problematic in a clinical setting. Autophagy impacts cellular metabolism, the proteome, and organelle numbers and quality, which alter cell functions in diverse ways. Moreover, autophagy influences the interaction between the tumor and the host by promoting stress adaptation and suppressing activation of innate and adaptive immune responses. Additionally, autophagy can promote a cross-talk between the tumor and the stroma, which can support tumor growth, particularly in a nutrient-limited microenvironment. Thus, the role of autophagy in cancer is determined by nutrient availability, microenvironment stress, and the presence of an immune system. Here we discuss recent developments in the role of autophagy in cancer, in particular how autophagy can promote cancer through suppressing p53 and preventing energy crisis, cell death, senescence, and an anti-tumor immune response.
Keywords: ATG; autophagy; cancer; chloroquine; mouse models.
© 2016 Amaravadi et al.; Published by Cold Spring Harbor Laboratory Press.
References
-
- Abe T, Toyota M, Suzuki H, Murai M, Akino K, Ueno M, Nojima M, Yawata A, Miyakawa H, Suga T, et al. 2005. Upregulation of BNIP3 by 5-aza-2′-deoxycytidine sensitizes pancreatic cancer cells to hypoxia-mediated cell death. J Gastroenterol 40: 504–510. - PubMed
-
- Aita VM, Liang XH, Murty VV, Pincus DL, Yu W, Cayanis E, Kalachikov S, Gilliam TC, Levine B. 1999. Cloning and genomic organization of beclin 1, a candidate tumor suppressor gene on chromosome 17q21. Genomics 59: 59–65. - PubMed
-
- Akada M, Crnogorac-Jurcevic T, Lattimore S, Mahon P, Lopes R, Sunamura M, Matsuno S, Lemoine NR. 2005. Intrinsic chemoresistance to gemcitabine is associated with decreased expression of BNIP3 in pancreatic cancer. Clin Cancer Res 11: 3094–3101. - PubMed
-
- Akalay I, Janji B, Hasmim M, Noman MZ, Andre F, De Cremoux P, Bertheau P, Badoual C, Vielh P, Larsen AK, et al. 2013. Epithelial-to-mesenchymal transition and autophagy induction in breast carcinoma promote escape from T-cell-mediated lysis. Cancer Res 73: 2418–2427. - PubMed
Publication types
MeSH terms
Grants and funding
- P30 CA072720/CA/NCI NIH HHS/United States
- R01 CA193970/CA/NCI NIH HHS/United States
- P01 CA114046/CA/NCI NIH HHS/United States
- R01 CA198015/CA/NCI NIH HHS/United States
- R01 CA157490/CA/NCI NIH HHS/United States
- R01 GM095567/GM/NIGMS NIH HHS/United States
- P50 CA174523/CA/NCI NIH HHS/United States
- R01 CA163591/CA/NCI NIH HHS/United States
- R01 CA169134/CA/NCI NIH HHS/United States
- P30 CA016520/CA/NCI NIH HHS/United States
- R01 CA188048/CA/NCI NIH HHS/United States
- R01 CA130893/CA/NCI NIH HHS/United States
- R01 CA188096/CA/NCI NIH HHS/United States
LinkOut - more resources
Full Text Sources
Other Literature Sources
Research Materials
Miscellaneous